Cargando…
A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours
BB-3644 is an oral, broad-spectrum matrix metalloproteinase inhibitor (MMPI) structurally related to marimastat and BB-94. It is also >10-fold more active than marimastat in inhibiting the processing of cell-bound TNF-α. Preclinical studies suggested a favourable toxicity profile when compared to...
Autores principales: | Wall, L, Talbot, D C, Bradbury, P, Jodrell, D I |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410175/ https://www.ncbi.nlm.nih.gov/pubmed/14970856 http://dx.doi.org/10.1038/sj.bjc.6601594 |
Ejemplares similares
-
The Pharmacological TAILS of Matrix Metalloproteinases and Their Inhibitors
por: Das, Nabangshu, et al.
Publicado: (2020) -
Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in the hair cycle
por: HOU, CHUN, et al.
Publicado: (2016) -
Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
por: Konings, I R H M, et al.
Publicado: (2010) -
Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
por: Tanaka, Komei, et al.
Publicado: (2013) -
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2005)